L
LPOXY Therapeutics, Inc.
LPOXY Therapeutics is developing a convenient, orally administered capsule to deliver OXYGEN directly to the bowel to help those with inflammatory bowel diseases
About LPOXY Therapeutics, Inc.
LPOXY Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2020 and headquartered in Platte City, Missouri. The company was co-founded by Dr. Larry D. Sutton, MD, PhD, and Dr. Porter W. Anderson, Jr., PhD, continuing a successful entrepreneurial partnership from a previous venture, Sopharmia, Inc., which was acquired in 2015. Dr. Sutton, who serves as CEO, brings a background as a physician-scientist with a PhD in chemistry and extensive experience in clinical microbiology, alongside a track record of founding and exiting companies. Dr. Anderson is a renowned immunologist and a member of the National Academy of Sciences, celebrated for his role in developing the Haemophilus influenzae type B (Hib) vaccine.
The company is focused on developing therapies to prevent and treat severe gastrointestinal diseases by delivering oxygen directly to the bowel. Its lead product candidate, SIDIPREV™ (also known as LP-102), is a first-in-class, orally administered, enteric-coated capsule designed to prevent Clostridioides difficile (C. diff) colitis, an infection designated by the CDC as an urgent public health threat. This non-antibiotic therapeutic works by releasing a metered dose of oxygen in the lower GI tract, creating an environment that is hostile to the anaerobic C. diff bacteria. This mechanism is designed to inhibit bacterial growth, suppress toxin production, and reduce mucosal inflammation. The primary market for SIDIPREV™ consists of hospitalized patients who are at high risk of C. diff infection due to factors like age and antibiotic use.
LPOXY operates on a virtual model, utilizing consultant services rather than a large in-house team, a structure modeled after Arixa Pharmaceuticals. In January 2025, the company acquired key assets from Xeno Biosciences Inc., including regulatory data and intellectual property from Phase I trials, which validated the safety of the core technology. The company's business strategy is centered on addressing a significant unmet medical need, as there are currently no approved therapies for the prevention of C. diff. Revenue generation is anticipated upon regulatory approval and commercialization of SIDIPREV™, which is being developed to align with hospital economics by potentially reducing costly complications. The company has secured a robust patent portfolio with over 15 patents.
As of September 2025, LPOXY Therapeutics announced it had signed a term sheet for a $28 million Series A financing round led by 5Horizons Ventures to fund a pivotal registrational trial named STOP-Cdiff. This randomized, placebo-controlled study will enroll approximately 500 high-risk, hospitalized patients. The trial is designed under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), which could accelerate the path to approval. The company aims to launch this trial in the third quarter of 2026 and target a regulatory filing in 2029. In addition to C. diff prevention, LPOXY is also exploring the application of its oxygen-delivery technology for the treatment of inflammatory bowel diseases (IBD).
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 55.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Infections and Infectious Diseases, Gastroenterology, Inflammatory Diseases, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $28M | $112M | Horizons Ventures | ↗ |
Growth signals
Latest recorded traffic for LPOXY Therapeutics, Inc. is 930 monthly website visits, up 17.7% over the last three months. LPOXY Therapeutics, Inc.'s team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LPOXY Therapeutics, Inc. in the Platte City ecosystem
The LPOXY Therapeutics, Inc. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LPOXY Therapeutics, Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LPOXY Therapeutics, Inc.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










